AusBiotech has formed a strategic partnership with Oktopi to enhance support for its members in the Australian life sciences sector.
The collaboration aims to provide AusBiotech members with access to Oktopi's AI-driven platform at discounted rates, further enriching the organization's Business Solutions Program. This initiative will connect professionals in biotechnology, medical technology, and health tech with customized tools and pricing to facilitate medicine development.
Rebekah Cassidy, CEO of AusBiotech, emphasized the importance of equipping organizations with innovative tools and knowledge to foster growth and commercialization in Australia's life sciences landscape. She expressed enthusiasm about the partnership, which aims to meet the unique needs of the sector while delivering significant cost savings for members.
Oktopi, described as the "world's first cognitive infrastructure for medicine development," integrates an AI-informed knowledge engine and peer review capabilities to enhance decision-making in drug development. Co-Founder and CEO Dr. Craig Rayner highlighted the partnership's potential to accelerate the Australian biotech ecosystem through responsible AI use, stating that Oktopi is designed to support expert teams in making more informed decisions.
This partnership not only reflects a growing trend of integrating AI in life sciences but also underscores the commitment to innovation in the Australian biotech sector. As organizations like AusBiotech and Oktopi collaborate, the potential for accelerated drug development and improved patient access increases significantly.